Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in most solid tumors as well as the bone marrows of some hematologic tumors.
The company announced today clinical trial results of the Phase 1 study of TH-302 in patients with advanced leukemia. Thirty-two patients with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) have been enrolled in the trial so far. The study is taking place at the MD Anderson Cancer Center in Houston, Texas.
The starting dose in the trial was 120 mg/m2 daily for 5 days of a 21-day cycle and the highest dose investigated in the study was 550mg/m2. At this higher dose, two patients developed dose limiting mucosal toxicity. The maximum tolerated daily dose of TH-302 was found to be 460mg/m2. The drug’s efficacy was evidenced by stabilization or reduction of bone marrow and peripheral blast counts.
The accumulating evidence of the importance of hypoxia in advanced leukemia and the initial findings that TH-302 can reduce blasts in patients with advanced leukemias is promising for Threshold Pharmaceuticals. For more information about the company and its drug candidates, please visit its website at www.thresholdpharm.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment